Navigation Links
Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Date:7/31/2008

ing, or IPO. Diluted EPS was $0.60 for the first half of the year, including $0.19 of non-cash stock-based compensation expense.

The Company completed its IPO on November 2, 2007. On a pro forma basis, assuming conversion of all outstanding preferred stock, diluted EPS for the three and six months ended June 30, 2007 would have been $0.30 and $0.40, respectively (see "Pro Forma Net Income Per Share" table below).

Gross profit for the second quarter of 2008 improved 94% to $16.6 million from $8.6 million for the second quarter of 2007, or 59.7% of revenues as compared to 61.3% of revenues, respectively. Gross margins reflect the impact of additional costs associated with stock-based compensation and the investment in additional personnel to support our growing operations. For the first half of 2008, gross profits totaled $29.7 million, improving 104% as compared to $14.6 million for the same period in 2007, with gross profit at approximately 59.3% of revenues for the first half of 2008 being effectively flat year-over-year.

Operating expenses for the second quarter of 2008 increased to $11.4 million from $4.7 million in the second quarter of 2007 and to $20.4 million in the first half of 2008 from $9.3 million during the same period in 2007. These expenses were higher primarily due to investment in additional personnel to support organizational growth efforts, stock-based compensation expense and the increased costs associated with operating as a public company. Operating income for the second quarter of 2008 was $5.2 million, or 18.6% of revenues, as compared to $3.9 million, or 27.7% of revenues, during the same period in 2007. Operating income was $9.3 million, or 18.6% of revenues for the first half of 2008, up from $5.2 million, or 21.3% of revenues, for the first half of 2007.

As of June 30, 2008, the Company's cash and cash equivalents and investment securities available-for-sale totaled $96.1 million. For the six months ended June
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genoptix Reports Strong Financial Results for First Quarter 2008
2. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
3. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
4. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
5. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
6. Genoptix Announces Pricing of Secondary Public Offering
7. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
8. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
9. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
10. Genoptix, Inc. Announces Pricing for Initial Public Offering
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... participation in music classes may benefit children,s language development, ... the nonprofit Harmony Project, which provides music education and ... two years, children who actively participated in the classes ... and reading, compared to those with lower levels of ... music classes occurred in the same areas of the ...
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... SIMpalm, a leading mobile app ... iPhone for its client, which allows users to keep ... specialized in finding the right wine. At the ... combined sensory, chemistry and wine information. All this information ... fingerprint.” Those wines that are close counterparts to one ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, ... the millions of American women who have migraine: The debilitating ... is no association between migraine and breast cancer risk," said ... Harvard Medical School. "There is no positive association, so there ... effect either." About 18 percent of American women and ...
Breaking Medicine News(10 mins):Health News:Music Classes Boost Language Skills, Study Says 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
... , WEDNESDAY, Jan. 26 (HealthDay News) -- As long as ... opponents convinced that these shots do more harm than good. ... expressed more vehemently than with the standard measles-mumps-rubella (MMR) childhood ... after the retraction last year by The Lancet ...
... -- Scientists have pinpointed two gene variants that protect hepatitis ... findings are detailed in two studies that appear online and ... . The ability to identify patients with the two ... that antiviral therapy is completed and the hepatitis C virus ...
... , WEDNESDAY, Jan. 26 (HealthDay News) -- Arizona Congresswoman ... Houston Wednesday morning after her doctors upgraded her condition ... her remarkable recovery from a gunshot wound to the ... Center determined that she could be moved to nearby ...
... Vascular and Interventional Radiology the monthly, peer-reviewed flagship ... major changes for 2011all directed at highlighting the ... and its lead journal. JVIR, which has been ... medical, minimally invasive, radiological, pathological and socioeconomic issues ...
... new target for the prevention of adverse immune responses identified ... been discovered by researchers at the University of South Florida,s ... and Brain Repair. Their findings are published online in ... The CD45 molecule is a receptor on the surface of ...
... its kind surgical quality improvement program for children has the ... be targeted for quality improvement efforts to prevent complications and ... College of Surgeons National Surgical Quality Improvement Program-Pediatric (ACS NSQIP ... of the Journal of the American College of Surgeons ...
Cached Medicine News:Health News:Fear of Vaccines Has a Long, Persistent History 2Health News:Fear of Vaccines Has a Long, Persistent History 3Health News:Fear of Vaccines Has a Long, Persistent History 4Health News:Rep. Giffords Moved to Rehab Facility 2Health News:Rep. Giffords Moved to Rehab Facility 3Health News:Journal of Vascular and Interventional Radiology debuts new look, reflects global impact 2Health News:Journal of Vascular and Interventional Radiology debuts new look, reflects global impact 3Health News:Stimulating the brain's immune response may provide treatment for Alzheimer's disease 2Health News:First pediatric surgical quality program shows potential to measure children's outcomes 2
(Date:12/17/2014)... NEW YORK , Dec. 17, 2014 /PRNewswire-USNewswire/ ... resonance imaging (MRI), the MRI market is seeing ... cardiovascular and breast MRI scans account for the ... providing a higher resolution of images, which are creating ... resonance imaging (MRI) market is growing at a ...
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or ... of $125 million aggregate principal amount of 3.75% Convertible ... offered and sold only to qualified institutional buyers pursuant ... as amended (the "Securities Act"). The Notes ... year, payable semiannually in arrears on June 15 and ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... Oct. 25 In 73 years, Dr. Katherine Jeter has ... required an ostomy, she not only provided specialized care, she ... battling a personal health crisis, she recovered and focused on ... to increase the number of nurses trained to meet the ...
... the Pennsylvania State Police are reminding motorists that driving ... can be just as dangerous as driving under the ... PennDOT will work with state and municipal police departments ... increased emphasis on driving under the influence of drugs ...
Cached Medicine Technology:73-Year-Old Educator Embarks on Personal Challenge to Cycle 3,100 Miles to Raise $200,000 for WOC Nursing Scholarships 2PennDOT, State Police Caution Motorists About Dangers of Driving Under Influence of Legal Drugs 2
Unipolar Atrial "J" Lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: